Arcadia Investment Advisors’s Perspective Therapeutics CATX Stock Holding History

Arcadia Investment Advisors’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-22	Closed	-$55	–	88
2022 Q4	$55	Hold	22	–	–	﹤0.01%	89
2022 Q3	$51	Hold	22	–	–	﹤0.01%	89
2022 Q2	$69	Hold	22	–	–	﹤0.01%	112
2022 Q1	$81	Hold	22	–	–	﹤0.01%	112
2021 Q4	$86	Hold	22	–	–	﹤0.01%	112
2021 Q3	$140	Hold	22	–	–	﹤0.01%	113
2021 Q2	$177	Hold	22	–	–	﹤0.01%	241
2021 Q1	$242	Hold	22	–	–	﹤0.01%	100
2020 Q4	$100	Hold	22	–	–	﹤0.01%	111
2020 Q3	$129	Hold	22	–	–	﹤0.01%	105
2020 Q2	$123	Hold	22	–	–	﹤0.01%	75
2020 Q1	$118	Hold	22	–	–	﹤0.01%	77
2019 Q4	$139	Hold	22	–	–	﹤0.01%	61
2019 Q3	$71	Hold	22	–	–	﹤0.01%	69
2019 Q2	$91	Hold	22	–	–	﹤0.01%	67
2019 Q1	$81	Hold	22	–	–	﹤0.01%	64
2018 Q4	$67	Hold	22	–	–	﹤0.01%	65
2018 Q3	$115	Hold	22	–	–	﹤0.01%	58
2018 Q2	$100	Hold	22	–	–	﹤0.01%	69
2018 Q1	$93	Hold	22	–	–	﹤0.01%	59
2017 Q4	$89	Buy	+22	New	+$102	﹤0.01%	66

Other funds holding CATX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OCM

Osterweis Capital Management San Francisco, California $2.12B AUM 32.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

TMWM

Taylor & Morgan Wealth Management Flint, Michigan $208M AUM 15.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Arcadia Investment Advisors's CATX Position: Q1 2023 in Review

Arcadia Investment Advisors sold out of Perspective Therapeutics (CATX) in Q1 2023, closing a stake of 22 shares — an estimated $55 sold.

Arcadia Investment Advisors first reported a position in CATX in Q4 2017 and held it in 21 quarters. The position peaked at $242 in Q1 2021. 42 funds tracked by Wall St. Rank hold CATX as of Q1 2023.

Arcadia Investment Advisors reported no remaining Perspective Therapeutics position as of Q1 2023 after selling out during the quarter.
Arcadia Investment Advisors sold 22 Perspective Therapeutics shares in Q1 2023, an estimated $55.
Arcadia Investment Advisors first reported a position in Perspective Therapeutics in Q4 2017 and held it in 21 quarters.
Arcadia Investment Advisors's Perspective Therapeutics position peaked at $242 in Q1 2021.
42 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2023.

Based on Arcadia Investment Advisors's 13F filing for Q1 2023, filed 19 Dec 2024.